Science News - August 25, 2026
Turku researchers uncover molecular mechanism behind aggressive colorectal cancer
Researchers at the University of Turku, working with France's Gustave Roussy Institute, have identified a molecular mechanism that lets an aggressive subtype of colorectal cancer shield itself from chemotherapy and spread through the abdominal cavity – and shown that antibodies already used against other cancers can disrupt the process.
Collaboration - August 19, 2026
New Nordic centre aims to strengthen glymphatic system research
The Lundbeck Foundation has awarded DKK 78 million to a pan-Nordic centre that will focus on research into the glymphatic system.
Collaboration - August 17, 2026
Nordic research network aims to strengthen our region’s position in advanced microscopy
The network has researchers from Iceland, Norway, Sweden, Finland and Denmark. “It is absolutely crucial that we work together in the Nordic Region, because this is a rapidly developing scientific field, and when we join forces across the Nordic countries, we can compare ourselves with larger countries such as France, Germany and Italy. The Nordic […]
Science News - August 12, 2026
Swedish study points to more precise Alzheimer’s blood tests
Researchers at the University of Gothenburg and their international colleagues have identified a seven-protein panel that could improve blood-based testing for Alzheimer’s disease.
Science News - August 10, 2026
Finnish research joins new transatlantic cardiovascular network
The Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki is joining ATHENA, a new five-year research network focused on the genetic and molecular mechanisms behind atherosclerosis.
Science News - July 31, 2026
New laboratory model could speed treatment development for rare, deadly melanomas
Researchers at the University of Turku have developed a new preclinical model that could help accelerate drug development for BAP1-deficient melanomas, a rare and highly aggressive form of melanoma that is resistant to current immunotherapies.